David Martin PhD
Stock Analyst at Bloom Burton
(4.73)
# 670
Out of 4,476 analysts
221
Total ratings
53.1%
Success rate
18.5%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSX: MDP Medexus Pharmaceuticals Inc. | Maintained: Buy | $6.00 | $5.14 | +16.73% | 13 | Jun 29, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $35 → $36 | $26.31 | +36.83% | 13 | Jun 29, 2026 | |
| TSXV: RX BioSyent Inc. | Maintained: Buy | $16.50 → $18.00 | $14.50 | +24.14% | 14 | Jun 4, 2026 | |
| TSX: HLS HLS Therapeutics Inc. | Maintained: Buy | $12.00 | $4.20 | +185.71% | 50 | May 19, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Maintained: Buy | $0.50 → $0.40 | $0.30 | +33.33% | 13 | May 15, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | $15 | $15.61 | -3.91% | 33 | May 11, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $11.00 → $12.00 | $9.91 | +21.09% | 28 | May 8, 2026 | |
| TSX: CRRX CareRx Corporation | Maintained: Buy | $5.50 → $5.00 | $3.48 | +43.68% | 11 | May 8, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Maintained: Buy | $19.88 | $9.53 | +108.60% | 5 | Apr 27, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Maintained: Buy | $4.00 → $5.00 | $1.54 | +225.73% | 3 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $74 | $60.96 | +21.39% | 8 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $6.24 | +653.21% | 7 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.52 → $4.00 | $0.395 | +912.66% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $8.11 | +10.97% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $19.40 | -28.49% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.20 → $19.00 | $19.32 | -1.66% | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $1.00 | $0.23 | n/a | 2 | Jul 6, 2025 |
Medexus Pharmaceuticals Inc.
Jun 29, 2026
Maintained: Buy
Price Target: $6.00
Current: $5.14
Upside: +16.73%
Zymeworks
Jun 29, 2026
Maintained: Buy
Price Target: $35 → $36
Current: $26.31
Upside: +36.83%
BioSyent Inc.
Jun 4, 2026
Maintained: Buy
Price Target: $16.50 → $18.00
Current: $14.50
Upside: +24.14%
HLS Therapeutics Inc.
May 19, 2026
Maintained: Buy
Price Target: $12.00
Current: $4.20
Upside: +185.71%
Microbix Biosystems Inc.
May 15, 2026
Maintained: Buy
Price Target: $0.50 → $0.40
Current: $0.30
Upside: +33.33%
Aurinia Pharmaceuticals
May 11, 2026
Maintained: Hold
Price Target: $15
Current: $15.61
Upside: -3.91%
Knight Therapeutics Inc.
May 8, 2026
Maintained: Buy
Price Target: $11.00 → $12.00
Current: $9.91
Upside: +21.09%
CareRx Corporation
May 8, 2026
Maintained: Buy
Price Target: $5.50 → $5.00
Current: $3.48
Upside: +43.68%
Eupraxia Pharmaceuticals Inc.
Apr 27, 2026
Maintained: Buy
Price Target: $19.88
Current: $9.53
Upside: +108.60%
PYC Therapeutics Limited
Mar 19, 2026
Maintained: Buy
Price Target: $4.00 → $5.00
Current: $1.54
Upside: +225.73%
Mar 9, 2026
Maintained: Buy
Price Target: $57 → $74
Current: $60.96
Upside: +21.39%
Mar 5, 2026
Maintained: Buy
Price Target: $47
Current: $6.24
Upside: +653.21%
Dec 11, 2025
Maintained: Buy
Price Target: $8.52 → $4.00
Current: $0.395
Upside: +912.66%
Nov 19, 2025
Maintained: Buy
Price Target: $9
Current: $8.11
Upside: +10.97%
Oct 21, 2025
Maintained: Buy
Price Target: $14
Current: $19.40
Upside: -28.49%
Jul 18, 2025
Maintained: Buy
Price Target: $20.20 → $19.00
Current: $19.32
Upside: -1.66%
Jul 6, 2025
Initiated Coverage: Buy
Price Target: $1.00
Current: $0.23
Upside: n/a